Erasca Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Erasca Inc
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
/ 
Frequently asked questions
To buy Erasca Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Erasca Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Erasca Inc is ERAS:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Erasca Inc has its primary listing on NASDAQ. You can trade Erasca Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Erasca Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Erasca Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Erasca Inc.